P087 Inhibition of pleural inflammation hampers with bleomycin-induced lung profibrotic toxicity.

Archive ouverte

Burgy, Olivier | Bellaye, Pierre-Simon, Bellaye | Causse, Sebastien | Boutanquoi, Pierre-Marie | Wettstein, Guillaume | Beltramo, Guillaume | Camus, Philippe | Garrido, Carmen | Goirand, Françoise | Bonniaud, Philippe

Edité par CCSD ; Oxford University Press (OUP) -

IF 2.824. International audience. The clinical use of bleomycin is restrained because of its lung toxicity with pulmonary fibrosis being the most devastating form. Toxic and idiopathic pulmonary fibrosis (PF) start classically in the subpleural area. It is known that 1) pleural mesothelial cells (PMCs) acquire a TGF-beta1-induced myofibroblast phenotype and 2) inflammation plays a significant role in fibrogenesis. The role of mesothelial cells in PF and in bleomycin lung toxicity has still to be investigated.C57Bl/6 mice were intravenously injected with bleomycin or NaCl. Repeated intravenous bleomycin induces a peculiar lung fibrotic response with 1) an histological peripheral distribution, 2) a collagen accumulation in pleural and subpleural area, 3) an overexpression of MMP-2, -9, HSP27, all involved in PMCs transformation and 4) a migration of PMCs into the lung....

Consulter en ligne

Suggestions

Du même auteur

LSC Abstract – Pleural inflammation is essential in bleomycin-induced lung toxicity

Archive ouverte | Burgy, Olivier | CCSD

IF 10.569 . International audience. Introduction: In patients, the therapeutic use of bleomycin (BLM), a potent anticancerous drug, is strongly restrained because of its lung toxicity with pulmonary fibrosis (PF) be...

Pleural inhibition of the caspase-1/IL-1β pathway diminishes profibrotic lung toxicity of bleomycin

Archive ouverte | Burgy, Olivier | CCSD

IF 3.751. International audience. Background: Idiopathic and toxic pulmonary fibrosis are severe diseases starting classically in the subpleural area of the lung. It has recently been suggested that pleural mesothel...

P105 Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity

Archive ouverte | Burgy, Olivier | CCSD

IF 2.824. International audience. Bleomycin is an anti-cancer drug used to treat different malignancies, mainly lymphomas, germ cell tumors. Unfortunately, bleomycin has major, pulmonary toxicity that affects 20% of...

Chargement des enrichissements...